MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

Study Summary

In this first-in human, phase I/IIa study, the safety and efficacy of \[212Pb\]VMT01, an alpha-particle emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R) is being evaluated as a monotherapy and in combination with nivolumab in subjects with unresectable and metastatic melanoma.

Conditions

Recurrent Melanoma (Skin)Metastatic Melanoma Melanoma Stage IV Melanoma Stage III

Interventions / Drugs

[203Pb]VMT01 [212Pb]VMT01 Nivolumab

View on ClinicalTrials.gov ↗

Sponsor

CATX

Perspective Therapeutics

Oncology

D38/100

Study Details

Enrollment300 participants

Primary Completion—

Lead SponsorPerspective Therapeutics

Data Retrieved2026-04-11 04:08:56.505113+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.